Stock APHB AMPLIPHI BIOSCIENCES CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Ampliphi Biosciences Corp Nyse

Equities

APHB

US03211P2020

Biotechnology & Medical Research

Search
See the results
Armata Pharmaceuticals : Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP PA02 in Non Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Form 8 K
Dec. 19
 PU
Armata Pharmaceuticals, Inc. Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Dec. 19
 CI
Armata Pharmaceuticals, Inc. Concludes Employment Agreement with Mina Pastagia as Chief Medical Officer
Dec. 04
 CI
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Nov. 20
 AQ
Armata Pharmaceuticals : Announces Third Quarter 2024 Results and Form 8 K
Nov. 13
 PU
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 13
 CI
Armata Pharmaceuticals : Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia Form 8 K
Nov. 12
 PU
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Nov. 12
 CI
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
24-09-06
 AQ
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
24-08-27
 AQ
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
24-08-16
 AQ
Armata Pharmaceuticals Announces Principal Financial Officer Changes
24-08-15
 CI
Armata Pharmaceuticals, Inc. Announces Appointment of David House as SVP of Finance, Effective August 16
24-08-15
 CI
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
24-08-14
 AQ
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
24-07-30
 CI
Armata Pharmaceuticals : 2024 Annual Meeting Proxy
24-07-25
 PU
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
24-07-12
 AQ
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
24-07-11
 AQ
Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection
24-07-11
 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
24-05-07
 CI
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
24-05-07
 MT
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K
24-03-22
 PU
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
24-03-21
 MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
24-03-21
 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
24-03-21
 CI
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARMP Stock
  4. APHB Stock
  5. News Ampliphi Biosciences Corp